SCHEMBL2215079

SCHEMBL2215079

CN1CCN(Cc2ccc(C(=O)Nc3ccc(Nc4nc(-c5cccc6c5oc5ccccc56)cc5ccnn45)cc3)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.44
ABL1 P00519 8/20 0.44
BCR P11274 5/20 0.43
PDGFRB P09619 3/20 0.43
SRC P12931 3/20 0.43
PDGFRA P16234 3/20 0.43
SYK P43405 2/20 0.43
KIT P10721 5/20 0.43
LCK P06239 6/20 0.41
CSF1R P07333 6/20 0.41
MAPK14 Q16539 4/20 0.41
EGFR P00533 4/20 0.41
KDR P35968 3/20 0.41
ERBB4 Q15303 1/20 0.41
FLT3 P36888 2/20 0.41
ERBB2 P04626 2/20 0.41
FYN P06241 2/20 0.41
LYN P07948 2/20 0.41
FGR P09769 2/20 0.41
BRAF P15056 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2214178 0.88 KDM4E (0.39) PDGFRAKITLMNATNIK
SCHEMBL2213958 0.87 KDM4E (0.37) LMNA
SCHEMBL2214452 0.86 ROCK2 (0.39) LMNACYP3A4
SCHEMBL2216183 0.86 ALDH1A1 (0.42) MAPK13LMNAHCKAURKAAURKB
SCHEMBL2215322 0.86 KDM4E (0.37) LMNA
SCHEMBL2215529 0.85 ALDH1A1 (0.38) BTKKDRLMNAAURKAAURKB
SCHEMBL2213218 0.85 TRPV1 (0.42) BTKSYKLMNA
SCHEMBL2214233 0.84 DNMT1 (0.42) ABL1BCRABL2LMNA
SCHEMBL2215221 0.84 MAPT (0.42) LMNAMAPK10AURKAAURKB
SCHEMBL2215080 0.84 LMNA (0.50) LMNATYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 BTK 3785/4885ABL1 1434/4885BCR 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.